

The Steinberg Law Group supports the FDA's approval of Opdivo in combination with Yervoy

The Steinberg Law Group supports the FDA's approval of Opdivo in combination with Yervoy

HOUSTON, TEXAS, USA, October 5, 2020 /EINPresswire.com/ -- On October 2, 2020, the U.S. Food and Drug Administration granted approval to Bristol-Myers Squibb Company for [Opdivo](#) (nivolumab) in combination with [Yervoy](#) (ipilimumab) for the first-line treatment of adults with inoperable malignant pleural [mesothelioma](#). This is the first drug regimen approved for mesothelioma in

16 years. Prior to the approval of Opdivo with Yervoy, pemetrexed with cisplatin/carboplatin, which the FDA approved in 2004, was the only treatment option for those with inoperable malignant pleural mesothelioma. The Steinberg Law Group is optimistic about the positive



We are affiliated with doctors around the country.

“

In 2004, [the] FDA approved pemetrexed in combination with cisplatin for [pleural malignant mesothelioma], and now patients now have an important, additional treatment option...”

Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence

effects of Opdivo in combination with Yervoy for patients who are unable to undergo aggressive mesothelioma surgery, which occurs in less than one-third of those diagnosed because the disease is often too advanced by the time of diagnosis.

The most common side effects of Opdivo in combination with Yervoy in patients with malignant pleural mesothelioma include: fatigue, musculoskeletal pain, rash, diarrhea, dyspnea (difficulty breathing), nausea, decreased appetite, cough and pruritis (itching). Yervoy can cause serious conditions known as immune-mediated side effects, including inflammation of healthy organs, such as

the lungs (pneumonitis), colon (colitis), liver (hepatitis), endocrine glands (endocrinopathies) and

kidneys (nephritis). Patients should tell their healthcare providers if they have immune system problems, lung or breathing problems, liver problems, have had an organ transplant, or are pregnant or plan to become pregnant before starting treatment.

Robert L. Steinberg
The Steinberg Law Group
+1 888-891-2200

[email us here](#)

Visit us on social media:

[Facebook](#)

[LinkedIn](#)



The Steinberg Law Group has the experiences, resources and results to obtain the maximum financial compensation for veterans

This press release can be viewed online at: <https://www.einpresswire.com/article/527759395>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.